Details for New Drug Application (NDA): 213762
✉ Email this page to a colleague
NDA 213762 describes ARFORMOTEROL TARTRATE, which is a drug marketed by Aiping Pharm Inc, Alembic, Aucta, Cipla, Dr Reddys, Glenmark Pharms Ltd, Lexenpharm, Lupin, Mankind Pharma, Micro Labs, Neocubes Pharma, Ritedose Corp, Saba Ilac Sanayi, Slate Run Pharma, Sun Pharm, Teva Pharms Usa, and Wilshire Pharms Inc, and is included in seventeen NDAs. It is available from sixteen suppliers. Additional details are available on the ARFORMOTEROL TARTRATE profile page.
The generic ingredient in ARFORMOTEROL TARTRATE is arformoterol tartrate. There are four drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the arformoterol tartrate profile page.
The generic ingredient in ARFORMOTEROL TARTRATE is arformoterol tartrate. There are four drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the arformoterol tartrate profile page.
Summary for 213762
| Tradename: | ARFORMOTEROL TARTRATE |
| Applicant: | Slate Run Pharma |
| Ingredient: | arformoterol tartrate |
| Patents: | 0 |
Pharmacology for NDA: 213762
| Mechanism of Action | Adrenergic beta2-Agonists |
Suppliers and Packaging for NDA: 213762
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 213762 | ANDA | Slate Run Pharmaceuticals | 70436-151 | 70436-151-57 | 30 POUCH in 1 CARTON (70436-151-57) / 1 VIAL in 1 POUCH (70436-151-19) / 2 mL in 1 VIAL |
| ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 213762 | ANDA | Slate Run Pharmaceuticals | 70436-151 | 70436-151-58 | 15 POUCH in 1 CARTON (70436-151-58) / 4 VIAL in 1 POUCH (70436-151-20) / 2 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INHALATION | Strength | EQ 0.015MG BASE/2ML | ||||
| Approval Date: | Jun 22, 2021 | TE: | AN | RLD: | No | ||||
Complete Access Available with Subscription
